CIMBALI
Tuesday 05 November 2024
  • DVG De Vecchi
  • La Cimbali

Nestlé divests its Palforzia business

This agreement follows Nestlé's announcement last year that it would conduct a strategic review of Palforzia. Nestlé will receive milestone payments and ongoing royalties from Stallergenes Greer

Must read

Dalla Corte
TME - Cialdy Evo
Demuslab

VEVEY, Switzerland – Nestlé announced today that is has divested Palforzia, its peanut allergy treatment business, to Stallergenes Greer, a biopharmaceutical company which specializes in the diagnosis and treatment of allergies. The transaction was closed upon signing.

This agreement follows Nestlé’s announcement last year that it would conduct a strategic review of Palforzia. Nestlé will receive milestone payments and ongoing royalties from Stallergenes Greer.

“We are confident that Stallergenes Greer will take Palforzia forward and ensure this unique treatment supports patients around the world,” said Greg Behar, CEO of Nestlé Health Science.

“At the same time, the divestiture allows Nestlé Health Science to focus on its core strengths and key growth drivers.”

There will be a customary transition period to ensure business continuity and give patients uninterrupted access to the treatment.

CIMBALI

Latest article

  • Franke Mytico
  • Gimoka
Demus Art of decaffeination